Workflow
眼科专科诊疗服务
icon
Search documents
何氏眼科涨2.14%,成交额2400.67万元,主力资金净流出174.89万元
Xin Lang Cai Jing· 2025-09-30 06:57
Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]
何氏眼科9月25日获融资买入436.50万元,融资余额6575.96万元
Xin Lang Cai Jing· 2025-09-26 01:36
Core Viewpoint - He Eye Hospital experienced a decline of 1.67% in stock price on September 25, with a trading volume of 29.49 million yuan, indicating potential market concerns regarding the company's performance [1] Financing Summary - On September 25, He Eye Hospital had a financing buy-in amount of 4.36 million yuan and a financing repayment of 3.73 million yuan, resulting in a net financing buy of 0.63 million yuan [1] - The total financing and securities balance for He Eye Hospital reached 65.76 million yuan, with the financing balance accounting for 2.02% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low financing position [1] - In terms of securities lending, there were no shares repaid or sold on September 25, with a remaining quantity of 100 shares and a securities lending balance of 2,065 yuan, which is above the 50th percentile level over the past year, suggesting a high securities lending position [1] Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province, and specializes in providing ophthalmic specialty diagnosis and treatment services [2] - The company's revenue composition includes: vision care services (30.24%), refractive surgery correction services (24.16%), non-surgical treatments (20.02%), cataract diagnosis and treatment services (13.68%), vitreoretinal diagnosis and treatment services (8.09%), other eye disease treatment services (3.20%), and other business income (0.61%) [2] - As of June 30, the number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Financial Performance - For the first half of 2025, He Eye Hospital reported a revenue of 560 million yuan, reflecting a year-on-year decrease of 4.22%, while the net profit attributable to shareholders was 44.32 million yuan, showing a significant year-on-year increase of 84.19% [2] Dividend Information - Since its A-share listing, He Eye Hospital has distributed a total of 348 million yuan in dividends, with 275 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder of He Eye Hospital is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.79 million shares, which is a decrease of 1.76 million shares compared to the previous period [3]
何氏眼科跌2.02%,成交额1599.53万元,主力资金净流入87.21万元
Xin Lang Cai Jing· 2025-09-23 02:27
Core Viewpoint - He Eye Hospital's stock price has experienced fluctuations, with a year-to-date increase of 2.14% but a significant decline in recent trading periods, indicating potential volatility in investor sentiment [2]. Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province. The company specializes in providing ophthalmic specialty diagnosis and treatment services [2]. - The revenue composition of He Eye Hospital includes: Vision services (30.24%), Refractive surgery correction services (24.16%), Non-surgical treatments (20.02%), Cataract diagnosis and treatment services (13.68%), Vitreoretinal diagnosis and treatment services (8.09%), Other ophthalmic diagnosis and treatment services (3.20%), and Other business income (0.61%) [2]. Financial Performance - As of June 30, 2025, He Eye Hospital reported a revenue of 560 million yuan, a year-on-year decrease of 4.22%. However, the net profit attributable to shareholders was 44.32 million yuan, reflecting a significant year-on-year increase of 84.19% [2]. - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for He Eye Hospital was 10,800, an increase of 15.03% from the previous period. The average circulating shares per person decreased by 13.07% to 7,684 shares [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund held 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3].
何氏眼科股价涨5.52%,融通基金旗下1只基金位居十大流通股东,持有279.47万股浮盈赚取340.95万元
Xin Lang Cai Jing· 2025-09-01 07:27
Group 1 - The core viewpoint of the news is the performance and financial status of He Eye Hospital Group, which saw a stock price increase of 5.52% to 23.33 CNY per share, with a total market capitalization of 3.687 billion CNY [1] - He Eye Hospital Group was established on October 15, 2009, and went public on March 22, 2022, primarily providing specialized ophthalmic diagnosis and treatment services, with medical services accounting for 69.15% of revenue, optical services for 30.24%, and other services for 0.61% [1] - The top circulating shareholder, Rongtong Fund, reduced its holdings in He Eye Hospital by 1.7584 million shares, now holding 2.7947 million shares, which represents 3.36% of the circulating shares [2] Group 2 - Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has achieved a year-to-date return of 21.07% and a one-year return of 41.78%, ranking 3789 out of 8254 and 3412 out of 8037 respectively [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 9 days, with the fund's total asset size at 4.223 billion CNY and a best return of 156.58% during his tenure [3]